Companies developing risky products for marketing must be excluded from risk assessment. However, the necessary preconditions for independence are in many cases are not fulfilled. This problem is related to concerns about the data produced for the approval processes and to the many recently published reports on risks and potential benefits of genetically engineered organisms.